Lars Molander

986 total citations
25 papers, 743 citations indexed

About

Lars Molander is a scholar working on Physiology, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Lars Molander has authored 25 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 9 papers in Molecular Biology and 7 papers in Psychiatry and Mental health. Recurrent topics in Lars Molander's work include Smoking Behavior and Cessation (8 papers), Nicotinic Acetylcholine Receptors Study (6 papers) and Respiratory and Cough-Related Research (5 papers). Lars Molander is often cited by papers focused on Smoking Behavior and Cessation (8 papers), Nicotinic Acetylcholine Receptors Study (6 papers) and Respiratory and Cough-Related Research (5 papers). Lars Molander collaborates with scholars based in Sweden, Denmark and United States. Lars Molander's co-authors include Börje Cronholm, E. Lunell, A. Randrup, J. A. Christensen, J. Buus Lassen, Richard F. Squires, J. Wahren, Karin Ekberg, Marie Lindgren and Ingmar Ros�n and has published in prestigious journals such as Psychopharmacology, Clinical Pharmacology & Therapeutics and Acta Psychiatrica Scandinavica.

In The Last Decade

Lars Molander

25 papers receiving 644 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Molander Sweden 16 257 240 150 124 108 25 743
W.Z. Potter United States 7 185 0.7× 205 0.9× 299 2.0× 196 1.6× 158 1.5× 11 771
I Degrell Hungary 15 137 0.5× 92 0.4× 221 1.5× 79 0.6× 71 0.7× 36 734
Ann‐Kathrine Granérus Sweden 20 458 1.8× 162 0.7× 379 2.5× 194 1.6× 73 0.7× 39 1.5k
Kim Lawson United Kingdom 20 216 0.8× 330 1.4× 280 1.9× 163 1.3× 189 1.8× 62 1.1k
D. Xeno Rasmusson United States 10 368 1.4× 125 0.5× 335 2.2× 63 0.5× 127 1.2× 14 901
C. G. Gottfries Sweden 23 347 1.4× 278 1.2× 508 3.4× 228 1.8× 253 2.3× 48 1.5k
Laurie Barclay United States 15 240 0.9× 84 0.3× 353 2.4× 70 0.6× 52 0.5× 34 863
William M. Petrie United States 12 107 0.4× 119 0.5× 296 2.0× 71 0.6× 218 2.0× 33 839
Philippe V. Cardon United States 13 115 0.4× 97 0.4× 123 0.8× 161 1.3× 168 1.6× 17 749
Kristin J. Holm 8 105 0.4× 97 0.4× 127 0.8× 67 0.5× 119 1.1× 9 639

Countries citing papers authored by Lars Molander

Since Specialization
Citations

This map shows the geographic impact of Lars Molander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Molander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Molander more than expected).

Fields of papers citing papers by Lars Molander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Molander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Molander. The network helps show where Lars Molander may publish in the future.

Co-authorship network of co-authors of Lars Molander

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Molander. A scholar is included among the top collaborators of Lars Molander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Molander. Lars Molander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Molander, Lars. (2001). Pharmacokinetics of nicotine in healthy elderly people. Clinical Pharmacology & Therapeutics. 69(1). 57–65. 67 indexed citations
2.
Molander, Lars & E. Lunell. (2001). Pharmacokinetic investigation of a nicotine sublingual tablet. European Journal of Clinical Pharmacology. 56(11). 813–819. 33 indexed citations
3.
Molander, Lars, E. Lunell, & Karl Olov Fagerström. (2000). Reduction of tobacco withdrawal symptoms with a sublingual nicotine tablet: a placebo controlled study. Nicotine & Tobacco Research. 2(2). 187–191. 24 indexed citations
4.
Molander, Lars. (2000). Pharmacokinetics of nicotine in kidney failure. Clinical Pharmacology & Therapeutics. 68(3). 250–260. 44 indexed citations
5.
Lunell, E., Lars Molander, Karin Ekberg, & J. Wahren. (2000). Site of nicotine absorption from a vapour inhaler - comparison with cigarette smoking. European Journal of Clinical Pharmacology. 55(10). 737–741. 68 indexed citations
6.
Lindgren, Marie, et al.. (1999). Electroencephalographic effects of intravenous nicotine - a dose-response study. Psychopharmacology. 145(3). 342–350. 43 indexed citations
7.
Lunell, E., et al.. (1997). Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/ in vivo correlation. European Journal of Clinical Pharmacology. 52(6). 495–500. 18 indexed citations
8.
Molander, Lars, et al.. (1996). Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clinical Pharmacology & Therapeutics. 59(4). 394–400. 31 indexed citations
9.
Lunell, E., Lars Molander, & M. Andersson. (1995). Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant. European Journal of Clinical Pharmacology. 48(1). 71–75. 20 indexed citations
10.
Lunell, E., et al.. (1995). Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms. European Journal of Clinical Pharmacology. 48-48(3-4). 19 indexed citations
11.
Woodson, Phillip P., K.O. Fagerström, Lars Molander, Jonathan H. Slade, & Jack E. Henningfield. (1993). Premier: A new nicotine delivery system - Studies on its environmental and biological impact. 4(3). 191–201. 3 indexed citations
12.
Larsson, H. Peter, et al.. (1982). Pharmacokinetics of parenteral and oral melperone in man. European Journal of Clinical Pharmacology. 23(2). 173–176. 5 indexed citations
13.
Molander, Lars. (1982). Effect of melperone, chlorpromazine, haloperidol, and diazepam on experimental anxiety in normal subjects. Psychopharmacology. 77(2). 109–113. 6 indexed citations
14.
Lund, Jacob, J. A. Christensen, Erik Bechgaard, Lars Molander, & H. Peter Larsson. (1979). Pharmacokinetics of Femoxetine in Man. Acta Pharmacologica et Toxicologica. 44(3). 177–184. 10 indexed citations
15.
Molander, Lars, et al.. (1976). Acute Effects of Oxazepam, Diazepam and Methylperone, alone and in Combination with Alcohol on Sedation, Coordination and Mood. Acta Pharmacologica et Toxicologica. 38(2). 145–160. 28 indexed citations
16.
Lassen, J. Buus, Richard F. Squires, J. A. Christensen, & Lars Molander. (1975). Neurochemical and pharmacological studies on a new 5HT-uptake inhibitor, FG4963, with potential antidepressant properties. Psychopharmacology. 42(1). 21–26. 74 indexed citations
17.
Molander, Lars & A. Randrup. (1974). Investigation of the Mechanism by which L‐DOPA Induces Gnawing in Mice. Acta Pharmacologica et Toxicologica. 34(5). 312–324. 15 indexed citations
18.
Cronholm, Börje & Lars Molander. (1964). MEMORY DISTURBANCES AFTER ELECTROCONVULSIVE THERAPY 5. Conditions one month after a series of treatments. Acta Psychiatrica Scandinavica. 40(2). 212–216. 42 indexed citations
19.
Cronholm, Börje & Lars Molander. (1961). MEMORY DISTURBANCES AFTER ELECTROCONVULSIVE THERAPY. Acta Psychiatrica Scandinavica. 36(1). 83–90. 11 indexed citations
20.
Cronholm, Börje & Lars Molander. (1957). MEMORY DISTURBANCES AFTER ELECTROCONVULSIVE THERAPY. Acta Psychiatrica Scandinavica. 32(3). 280–306. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W.Z. Potter Breakdown of academic impact, for papers by I Degrell Breakdown of academic impact, for papers by Ann‐Kathrine Granérus Breakdown of academic impact, for papers by Kim Lawson Breakdown of academic impact, for papers by D. Xeno Rasmusson Breakdown of academic impact, for papers by C. G. Gottfries Breakdown of academic impact, for papers by Laurie Barclay Breakdown of academic impact, for papers by William M. Petrie Breakdown of academic impact, for papers by Philippe V. Cardon Breakdown of academic impact, for papers by Kristin J. Holm
Rankless by CCL
2026